Portfolio Planning





For most of a product’s development time its viability is uncertain. Companies spend a great deal of money in preclinical testing and clinical development to prove that the product works, and does so safely.


Starting with the earliest research explorations, and extending through clinical development and into post-commercialization, companies have any number of potential projects competing for limited company resources for further development. The question becomes, “Which ones should we fund”?


At J.T. Gram & Associates, we answer this question by constructing comparable models using similarly derived evidence to provide apples to apples comparisons that offer actionable differentiation.


Beginning with an understanding of the therapeutic index of each development candidate, we then generate risk-adjusted patient-based forecast models that provides our clients with a reality-based assessment on which to base comparisons for opportunity planning and prioritization.



Need help on commercial side of the Oncology business?

Call Us: (760) 842-1895 or Email: john.gram@jtgram.com